Rituximab, B-lymphocyte depletion, and preservation of beta-cell function

New England Journal of Medicine

Volumn 361, Issue 22, 2009, Pages 2143-2152

  Pescovitz, Mark D ^a   Greenbaum, Carla J ^b   Krause Steinrauf, Heidi ^c   Becker, Dorothy J ^d   Gitelman, Stephen E ^e   Goland, Robin ^f   Gottlieb, Peter A ^g   Marks, Jennifer B ^h   McGee, Paula F ^c   Moran, Antoinette M ⁱ   Raskin, Philip ^j   Rodriguez, Henry ^a   Schatz, Desmond A ^k   Wherrett, Diane ^l   Wilson, Darrell M ^m   Lachin, John M ^c   Skyler, Jay S ^h  

^a INDIANA UNIVERSITY   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPHENHYDRAMINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; PARACETAMOL; PLACEBO; RITUXIMAB;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELL SUBPOPULATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSPNEA; FEMALE; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TEST MEAL; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AREA UNDER CURVE; B-LYMPHOCYTES; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; INSULIN-SECRETING CELLS; MALE; YOUNG ADULT;

EID: 70449480577     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0904452     Document Type: Article

References (35)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
2. Schernthaner G. Progress in the immunointervention of type-1 diabetes mellitus. Horm Metab Res 1995;27:547-554 (Pubitemid 26024220)
3. Mahon JL, Dupre J, Stiller CR. Lessons learned from the use of cyclosporine for insulin-dependent diabetes mellitus: the case for immunotherapy for insulin-dependent diabetics having residual insulin secretion. Ann N Y Acad Sci 1993;696:351-363 (Pubitemid 24062807)
4. Feutren G, Mihatsch M. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-1660
5. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3- antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608 (Pubitemid 41007846)
6. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698 (Pubitemid 34547482)
7. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920
8. Noorchashm H, Lieu YK, Noorchashm N, et al. I-Ag7-mediated antigen presentation by B lymphocytes is critical in over-coming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol 1999;163:743-750 (Pubitemid 29328081)
9. Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 2001;13:1583-1593 (Pubitemid 33133885)
10. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40- stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-2843 (Pubitemid 36667155)
11. Serreze DV, Silveira PA. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Curr Dir Autoimmun 2003;6:212-227
12. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-4718 (Pubitemid 32954353)
13. Kim H-J, Krenn V, Steinhauser G, Berek C. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 1999; 162:3053-3062 (Pubitemid 29309336)
14. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-350
15. Noorchashm H, Greeley SA, Naji A. The role of T/B lymphocyte collaboration in the regulation of autoimmune and alloimmune responses. Immunol Res 2003; 27:443-450 (Pubitemid 36995024)
16. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997;46:941-946 (Pubitemid 27220992)
17. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036-1040 (Pubitemid 34940796)
18. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445 (Pubitemid 24030569)
19. Pescovitz MD. Rituximab, an anti- CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-866 (Pubitemid 44356635)
20. Pescovitz MD. Idem. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr Transplant 2004;8:9-21.
21. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264 [Erratum, Diabetes 2004;53:1934.]
22. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
23. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-125 (Pubitemid 350273646)
24. Demidenko E. Mixed models: theory and applications. Hoboken, NJ: John Wiley, 2004.
25. Yilmaz MT, Devrim AS, Biyal F, et al. Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results. Diabetes Res Clin Pract 1993;19: 151-162 (Pubitemid 23131984)
26. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-2589 (Pubitemid 39062719)
27. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non- Hodgkin's lymphoma. Ann Oncol 1999; 10:655-661
28. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004;4:1357-1360 (Pubitemid 39013585)
29. Emery P, Fleischmann RM, Filipowicz- Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-1400 (Pubitemid 44497758)
30. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing- remitting multiple sclerosis. N Engl J Med 2008;358:676-688 (Pubitemid 351240747)
31. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47: 1013-1017 (Pubitemid 44102962)
32. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146-2154 (Pubitemid 36959194)
33. Bearden CM, Agarwal A, Book BK, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005;5:50-57 (Pubitemid 40095127)
34. Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest 1971;50:2559-2568
35. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti- CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:2652-2661